Phase 2 Leucine Diet Trial Combined With Chemoimmunotherapy for Advanced Gastric Cancer
Summary
NIH ClinicalTrials.gov registered a Phase 2 study (NCT07537348) evaluating a leucine-restricted diet combined with chemotherapy and immunotherapy in patients with advanced gastric cancer. The trial will assess safety, tolerability, tumor response rates, and 1-year survival outcomes. No compliance obligations or regulatory actions are imposed by this registry entry.
What changed
NIH ClinicalTrials.gov published registration details for a Phase 2 clinical trial studying leucine-restricted diet in combination with standard chemotherapy and immunotherapy for advanced gastric cancer patients. The trial targets adults and will evaluate safety, tumor response rates, and 1-year survival outcomes. This is a registry entry documenting an active clinical investigation.
Healthcare providers and clinical investigators may encounter this trial as a potential referral or collaborative research opportunity. Patients with advanced gastric cancer may seek enrollment information. No regulatory compliance obligations or reporting requirements arise from this ClinicalTrials.gov registration.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
Phase 2 NCT07537348 Kind: PHASE2 Apr 17, 2026
Abstract
Based on existing literature, we posit that a leucine-restricted diet is safe and well-tolerated in patients with advanced gastric cancer receiving combined chemotherapy and immunotherapy. Patients adhering to this dietary regimen exhibit a significant reduction in serum leucine concentrations, with no notable impact on the serum levels of other amino acids. Furthermore, leucine restriction promotes the activation of immune cells within the tumor microenvironment. When applied in conjunction with chemotherapy and immunotherapy for advanced gastric cancer, this approach demonstrates synergistic anti-tumor efficacy. It is expected to enhance tumor response rates , improve the 1-year survival rate, prolong overall survival (OS), and ultimately optimize patient prognosis.
Conditions: Advanced Gastric Cancer
Interventions: Lucine-restricted diet
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.